EMVision achieves first-responder milestone with the manufacture and development of bedside scanners.
EMVision, a medical device company focused on the development and commercialisation of medical imaging technology, is pleased to advise that it has successfully achieved an important milestone for the Company’s First Responder (2nd Gen) device under the Commonwealth of Australia Medical Research Future Fund (MRFF) program in partnership with the Australian Stroke Alliance (ASA).
Achievement of this milestone has resulted in EMVision receiving a $600,000 milestone payment from the ASA under the program.
The Milestone activities have focused on extensive end-user requirements gathering, with workshops held with VIC Ambulance, NSW Ambulance and the Royal Flying Doctor Service, among others, to ensure that the device being developed is fit for purpose, easy to operate and can integrate seamlessly into clinical workflows. Alongside these activities, an advanced concept for the 2nd Gen device has progressed positively.
Leveraging the core technology from EMVision’s 1st Gen in-hospital bedside scanner, the 2nd Gen first responder scanners’ proposed design includes a new hybrid antenna array, proprietary coupling cap and integrated neck, head and shoulder support. An initial prototype of the array is targeted for later this year. The regulatory strategy for EMVision’s 2nd Gen pre-hospital device intends to employ an expedited path to FDA clearance by leveraging the 1st Gen in-hospital device as a predicate device.
“We have made important progress with the first responder version while working in parallel on our 1st Gen in-hospital device,” noted EMVision CEO, Dr Ron Weinberger. “The extensive work done by our team will ensure that the device is fit for purpose and meets all the end-user needs, a critical part of the design process. We look forward to providing further updates on the achievement of our upcoming milestones for both devices in the near term.”
Under a Project Agreement with the ASA, EMVision will receive a total of $8m of non-dilutive cash funding ($6.2m remaining) in staged payments over the five-year project, weighted to the earlier years. The funding will support EMVision’s development and clinical validation of its planned first responder model for air and road ambulances (2nd Gen device), commencing with ongoing validation of EMVision’s portable brain scanner’s diagnostic capabilities in the hospital environment (1st Gen device). The funding is contingent on the project progressing in a manner that warrants continued funding at each stage and the ongoing achievement of project milestones.